Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
||Peter Kozuch, MD
| Time frame of study:
|Location of Study:
Mount Sinai Beth Israel
St.Luke's-Mount Sinai West
Continuum Cancer Research Program
The combination of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) may be better than other combinations used to treat earlier stage pancreatic cancer patients with resectable (able to be cut out), borderline resectable, and locally advanced pancreatic adenocarcinoma. Though all of the drugs in this study have been approved by the FDA, their combination is investigational. The purpose of this study is to evaluate the effects of CAPOXIRI (good and bad) on you and your cancer.
- 18 years of age or older
- Initial diagnosis must have occurred ≤ 42 days prior to patient consent
- No prior chemotherapy, immunotherapy, or radiotherapy for pancreatic adenocarcinoma
- There must be no extra-pancreatic spread of disease
- Patients must not have class II greater congestive heart failure or unstable angina pectoris, uncontrolled hypertension or arrhythmias, active bacterial infections, or unstable diabetes mellitus.
Please call for more information.